C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures European Medicines Agency Qualification Opinion For Enrichment Biomarker In ADPKD

TUCSON, Ariz.--(BUSINESS WIRE)--The Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) rendered a positive qualification opinion to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for total kidney volume (TKV) as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Help employers find you! Check out all the jobs and post your resume.